2 Dose Regimens of Telaprevir in Comb. w/Pegasys&Copegus

ID Number 08-0385

Principal Investigator(s)
Douglas Dieterich

Department(s) or Division(s)
Liver Diseases


The purpose of this study is to learn more about the safety and effectiveness of the study drug, called telaprevir, when it is combined with peginterferon a-2a (Pegasys®) and ribavirin (Copegus®) and given to patients with hepatitis C virus (HCV) who have never been treated for their HCV.

Contact Information
Douglas Dieterich, MD

Recruiting Patients: No